Historical Stock Price
ACER historical stock prices picture
Acer Therapeutics (ACER) has the following price history information. Looking back at ACER historical stock prices for the last five trading days, on October 17, 2019, ACER opened at $3.22, traded as high as $3.27 and as low as $3.03, and closed at $3.06. Trading volume was a total of 63.50K shares. On October 18, 2019, ACER opened at $3.24, traded as high as $3.32 and as low as $2.96, and closed at $3.00. Trading volume was a total of 51.80K shares. On October 21, 2019, ACER opened at $3.05, traded as high as $3.20 and as low as $3.03, and closed at $3.14. Trading volume was a total of 41.20K shares. On October 22, 2019, ACER opened at $3.14, traded as high as $3.47 and as low as $3.14, and closed at $3.38. Trading volume was a total of 75.00K shares. On October 23, 2019, ACER opened at $3.38, traded as high as $3.47 and as low as $3.14, and closed at $3.34. Trading volume was a total of 28.20K shares.

ACER Historical Stock Prices By Date:

ACER historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acer Therapeutics shares, starting with a $10,000 purchase of ACER, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/23/2009
End date: 10/23/2019
Start price/share: $24.17
End price/share: $3.34
Dividends collected/share: $0.00
Total return: -86.18%
Average Annual Total Return: -17.95%
Starting investment: $10,000.00
Ending investment: $1,381.39
Years: 10.01
Date Open High Low Close Volume
10/17/2019 $3.22 $3.27 $3.03 $3.06 63.50K
10/18/2019 $3.24 $3.32 $2.96 $3.00 51.80K
10/21/2019 $3.05 $3.20 $3.03 $3.14 41.20K
10/22/2019 $3.14 $3.47 $3.14 $3.38 75.00K
10/23/2019 $3.38 $3.47 $3.14 $3.34 28.20K
Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with unmet medical need. Co.'s pipeline includes three clinical-stage candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders and Maple Syrup Urine Disease; and osanetant for the treatment of various neuroendocrine disorders.
Date Close
10/17/2019$3.06
10/18/2019$3.00
10/21/2019$3.14
10/22/2019$3.38
10/23/2019$3.34
ACER is categorized under the Healthcare sector; below are some other companies in the same sector:

ACET Historical Stock Prices
ACHC Historical Stock Prices
ACHN Historical Stock Prices
ACHV Historical Stock Prices
ACOR Historical Stock Prices
ACRS Historical Stock Prices
ACRX Historical Stock Prices
ACST Historical Stock Prices
ACT Historical Stock Prices
ACUR Historical Stock Prices

Also explore: ACER shares outstanding history


ACER Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.